Shares of Intra-Cellular Therapies ITCI were unchanged after the company reported Q1 results.
Quarterly Results
Earnings per share rose 10.96% over the past year to ($0.65), which beat the estimate of ($0.80).
Revenue of $15,878,000 rose by 1366.11% year over year, which missed the estimate of $16,500,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Intra-Cellular Therapies hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: May 10, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/c6x5yerd
Price Action
Company's 52-week high was at $40.01
52-week low: $16.90
Price action over last quarter: down 1.13%
Company Description
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.